Composition:
Each CAPO-THIAZIDE LS tablet contains 25mg captopril and 12.5mg hydrochlorothiazide.
Mechanism of Action:
Captopril is a specific competitive inhibitor of angiotensin converting enzyme, and hydrochlorothiazide is a diuretic-antihypertensive agent. Captopril and hydrochlorothizide lower blood pressure by different complementary mechanisms. With diuretic treatment, blood pressure and blood volume fall resulting in a rise in angiotensin II levels, which tend to blunt the hypotensive effect. Captopril blocks this rise in angiostensin II.
Indications:
For the treatment of mild to moderate hypertension.
Dosage:
Adults: Usual dose is one tablet CAPO-THIAZIDE daily. A daily dose of 2 tablets CAPO-THIAZIDE should not be exceeded.
Elderly: The dose should be kept as low as possible to achieve adequate blood pressure control. In some patients one tablet of CAPO-THIAZIDE LS is enough to control blood pressure.
Side - Effects:
It may occur: a decrease in blood components (aplastic anemia) may occur; Elevated blood urea and creatinine, elevated serum potassium and acidosis; Tachycardia; Rashes, mild pruritus, photo-sensitivity; Gastric irritation, abdominal pain, and weight–loss; Hyperuricaemia may occur, or gout is precipitated by thiazide, in certain patients, Hyperglycemia; Such as cough, orthostatic hypotension.
Contra - Indications:
In patients with anuria or hypersensitivity to any sulphonamide derived drug, or patients with aortic stenosis.
Drug Interactions:
It should not be used with immuno-suppressants such as azathioprine, cyclophosphamide, because it may cause blood-dyscrasias. It should not be used with allopurinol, procainamide. A combination of lithium and ACE inhibitors may increase concentration of lithium in serum. Indomethacine and non-steroidal anti - inflammatory drugs may reduce anti-hypertensive effect. Minoxidil increases the anti - hypertensive effect. With probencid, the renal clearance of Product is reduced.
Precautions:
- It should be used with caution, in patients with impaired renal function or progressive kidney diseases, because of its known risks associated with alterations in fluid electrolyte balance.
- During treatment, all patients should be instructed to report any sign of infection. A differential white - blood cell count should be performed.
- The product and other concomitant medications should be stopped if neutropenia (less than 1000 / mm3) is detected. In most patients, neutrophil counts rapidly return to normal upon stopping captopril.
- The clinical signs of thiazide, induced fluid or electrolyte imbalance should be observed. As captopril reduces the production of aldosterone. Its combination with hydrochlorothiazide may minimize diuretic-induced hypokalaemia. However, some patients may still require potassium supplements.
Use in Pregnancy and Lactation:
It should not be used in pregnancy and in women of child bearing potentiality, unless protected by effective contraception, and it should not be used also during lactation.